urea, C-14
Trade name: pytest
Approved
May 9, 1997
Urea C-14 is a urea molecule radiolabelled with a radioactive carbon-14. Urea C-14 Breath Test is indicated for use in the detection of gastric urease as an aid in the diagnosis of H.pylori infection in the human stomach. The test utilizes a liquid scintillation counter for the measurement of CO in breath samples. To detect H.pylori, urea labeled with C is swallowed by the patient. If gastric urease from H.pylori is present, urea is split to form CO and NH at the interface between the gastric epithelium and lumen and CO is absorbed into the blood and exhaled in the breath. Antibiotics, proton pump inhibitors, sucralfate, and bismuth preparations are known to suppress H.pylori. Ingestion of antibiotics or bismuth within 4 weeks and proton pump inhibitors or sucralfate within 2 weeks prior to performing the test may give false negative results. — NCATS
Clinical trial activity
1 trials · 3 clinical orgs · 1 marketing orgs
Earliest trial started Nov 6, 2024 (NCT07224048)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Diagnostic agent
- contrast mediumRadiopaque
contrast medium radiopaque
Approval history
- approvedPriority reviewMay 9, 1997
Chemistry & pharmacology
SMILES
N[14C](N)=O- Mol. weight
- 62.0478 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- NCATSWBZ6M63TEE ↗
- ChEMBLCHEMBL2096635 ↗
Also known as
- 14c-urea
- 14c-urea
- 14c-urea
- carbon 14 urea
- carbon 14 urea
- carbon 14 urea
- carbon-14 urea
- carbon-14 urea
- carbon-14 urea
- pytest
- pytest
- pytest
- pytest kit
- pytest kit
- urea (14c)
- urea (14c)
- urea (14c)
- urea (14c)
- urea 14 c
- urea 14 c
- urea-14c
- urea-14c
- urea-14c
- urea c 14
- urea c 14
- urea c 14
- urea c 14
- urea c 14
- urea c 14
- urea c-14
- urea c-14
- urea, c-14
- urea, c-14
- urea, c-14
- urea, c-14
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07224048 | Phase 4 | Nov 6, 2024 | NRG Oncology, Phathom Pharmaceuticals, Inc., University of Miami |
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Phathom Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2024 |
| University of Miami | Academic/Hospital | 1 | 1 | 1 | 2024 |